KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
KIORA PHARMACEUTICALS, INC. (KPRX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $9.41 per share as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-07
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $9.41.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $18.76.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $8.10.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $22.39.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $9.41 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $18.76 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $8.10 10-K · filed 2026-03-25 | |
| 2025-09-30 | $22.39 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $34.98 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $37.13 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $21.15 10-K · filed 2026-03-25 | |
| 2024-09-30 | $56.79 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $96.70 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $10.26 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $41.43 10-K · filed 2025-03-25 | $4.26 10-K · filed 2024-03-25 |
| 2023-09-30 | $16.58 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $285.03 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $306.00 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $36.92 10-K · filed 2024-03-25 | |
| 2022-09-30 | $540.91 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $16.69 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $18.57 10-Q · filed 2022-07-08 | |
| 2021-12-31 | $426.25 10-K · filed 2023-03-23 | $10.43 10-K · filed 2022-04-15 |
| 2021-09-30 | $937.37 10-Q · filed 2022-11-09 | $12.66 10-Q · filed 2021-11-15 |
| 2021-06-30 | $24.25 10-Q · filed 2022-08-12 | $15.71 10-Q · filed 2021-08-12 |
| 2021-03-31 | $16.00 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $20.90 10-K/A · filed 2022-07-07 | |
| 2020-09-30 | $20.90 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $20.90 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $21.67 10-Q · filed 2021-05-12 | |
| 2019-12-31 | $27.42 10-K · filed 2020-03-04 | |
| 2019-09-30 | $27.68 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $27.20 10-Q · filed 2020-08-06 | $1.81 10-Q · filed 2019-08-08 |
| 2019-03-31 | $27.20 10-Q · filed 2020-05-06 | |
| 2018-09-30 | $33.74 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $2.29 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |